S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
M Telen,
S Saraf,
K Cruz,
M Idowu,
T Kalfa,
I Osunkwo,
R Hagar,
J Geib,
S Forsyth,
P Schroeder,
E Wu,
P Kelly,
R Brown
Affiliations
M Telen
1 Duke University, Durham, UNITED STATES
S Saraf
2 University of Illinois, Chicago, UNITED STATES
K Cruz
3 Advanced Pharma, Miami, UNITED STATES
M Idowu
4 Memorial Hermann-Texas Medical Center, Houston, UNITED STATES
T Kalfa
5 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES
I Osunkwo
6 Levine Cancer Institute, Atrium Health, Charlotte, UNITED STATES
R Hagar
7 UCSF Benioff Children’s Hospital San Francisco, Oakland, UNITED STATES
J Geib
8 Forma Therapeutics, Inc, Watertown, UNITED STATES
S Forsyth
8 Forma Therapeutics, Inc, Watertown, UNITED STATES
P Schroeder
8 Forma Therapeutics, Inc, Watertown, UNITED STATES
E Wu
8 Forma Therapeutics, Inc, Watertown, UNITED STATES
P Kelly
8 Forma Therapeutics, Inc, Watertown, UNITED STATES
R Brown
9 Children’s Healthcare of Atlanta, Atlanta, UNITED STATES
